Open AccessCombinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
Author(s) -
Helena Pópulo,
Beatriz Domingues,
Cristina Sampaio,
José Manuel Lopes,
Paula Soares
Publication year - 2021
Publication title -
journal of experimental pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.555
H-Index - 12
ISSN - 1179-1454
DOI - 10.2147/jep.s297831
Subject(s) - vemurafenib , melanoma , everolimus , pi3k/akt/mtor pathway , medicine , mapk/erk pathway , cancer research , trametinib , cell growth , mek inhibitor , pharmacology , targeted therapy , cell culture , apoptosis , cancer , oncology , signal transduction , biology , metastatic melanoma , genetics , biochemistry
Melanoma accounts for only 1% of all skin malignant tumors; however, it is the deadliest form of skin cancer. Since 2011, FDA (Food and Drug Administration) approved several novel therapeutic strategies, such as MAPK pathway targeted therapies, to treat cutaneous melanoma patients. However, their improvements in overall survival were limited, due to the development of resistance.